Trial Profile
A Phase Ib/IIa Single-arm, Open-label Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Including Chronic Phase Patients Who Have Failed Initial Tyrosine Kinase Inhibitor (TKI) Therapy, Accelerated or Blast Phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Prexigebersen (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bio-Path Holdings
- 26 May 2020 Status changed from recruiting to withdrawn prior to enrolment as no enrollement occurred.
- 23 Jan 2019 Planned End Date changed from 1 Nov 2020 to 1 Dec 2021.
- 23 Jan 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2020.